NM_000642.3(AGL):c.1484A>G (p.Tyr495Cys) AND Glycogen storage disease type III

Clinical significance:Uncertain significance (Last evaluated: Aug 2, 2020)

Review status:1 star out of maximum of 4 stars

criteria provided, single submitter

Based on:
1 submission [Details]
Record status:

Allele description [Variation Report for NM_000642.3(AGL):c.1484A>G (p.Tyr495Cys)]

NM_000642.3(AGL):c.1484A>G (p.Tyr495Cys)

AGL:amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Genomic location:
Preferred name:
NM_000642.3(AGL):c.1484A>G (p.Tyr495Cys)
  • NC_000001.11:g.99877701A>G
  • NG_012865.1:g.32618A>G
  • NM_000028.2:c.1484A>G
  • NM_000642.3:c.1484A>GMANE SELECT
  • NM_000643.2:c.1484A>G
  • NM_000644.2:c.1484A>G
  • NM_000646.2:c.1436A>G
  • NP_000019.2:p.Tyr495Cys
  • NP_000633.2:p.Tyr495Cys
  • NP_000634.2:p.Tyr495Cys
  • NP_000635.2:p.Tyr495Cys
  • NP_000637.2:p.Tyr479Cys
  • NC_000001.10:g.100343257A>G
Protein change:
Molecular consequence:
  • NM_000028.2:c.1484A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_000642.3:c.1484A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_000643.2:c.1484A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_000644.2:c.1484A>G - missense variant - [Sequence Ontology: SO:0001583]
  • NM_000646.2:c.1436A>G - missense variant - [Sequence Ontology: SO:0001583]


Glycogen storage disease type III (GSD3)
Glycogen storage disease type 3; Forbes disease; Cori disease; See all synonyms [MedGen]
MONDO: MONDO:0009291; MedGen: C0017922; Orphanet: 366; OMIM: 232400

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
SCV001555706Invitaecriteria provided, single submitter
Uncertain significance
(Aug 2, 2020)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing



Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]

Details of each submission

From Invitae, SCV001555706.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)


This sequence change replaces tyrosine with cysteine at codon 495 of the AGL protein (p.Tyr495Cys). The tyrosine residue is moderately conserved and there is a large physicochemical difference between tyrosine and cysteine. This variant is present in population databases (rs746119079, ExAC 0.006%). This variant has not been reported in the literature in individuals with AGL-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: Deleterious; PolyPhen-2: Probably Damaging; Align-GVGD: Class C0). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Apr 18, 2021

Support Center